TOWA GENERIC
-
Formulation
click here
Development -
Product Lineup
click here -
Kusuri-no-Shiori®
click here
List
NEWS
-
2025/05/20
NEW
Japan’s first extended-release Rivastigmine transdermal formulation (twice-weekly dosage), “RIVALUEN® LA Patch 25.92 mg / 51.84 mg,” launched and listed in the NHI drug price list
-
2025/05/15
NEW
Notice of Revisions of Financial Objectives of the 6th Medium-term Business Plan (2024-2026) PROACTIVE Ⅲ
-
2025/05/15
NEW
FY2024 Supplementary Material of Financial Results
-
2025/05/15
NEW
Consolidated Financial Results for the Year Ended March 31, 2025(Based on Japanese GAAP)
-
2025/05/07
NEW
Notice of Revisions of Financial Forecasts